Tumor MHCII immunity requires in situ antigen presentation by cancer-associated fibroblasts.
Dimitra Kerdidani(Alexander Fleming Biomedical Sciences Research Center), Maria Tsoumakidou(National and Kapodistrian University of Athens)
Cited by 0
Related Papers
Tumor MHCII immunity requires in situ antigen presentation by cancer-associated fibroblasts
|bioRxiv (Cold Spring Harbor Laboratory)|2020|2